Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CARD PHARM : Cardiome to Hold Conference Call to Discuss First Quarter Results and Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 11:56pm CET

Vancouver, Canada, July 25th, 2011 ? Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced it will hold a conference call to discuss Q1-2011 financial results and to provide a corporate update.

To access the conference call, please dial 416-340-2217 or 866-696-5910 and reference conference 6435784 . There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome?s website at www.cardiome.com .

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through August 26th, 2011. Please dial 905-694-9451 or 800-408-3053 and enter code 7372760# to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

For Further Information:  

Cardiome Investor Relations  (604) 676-6993 or Toll Free: 1-800-330-9928 Email: ir@cardiome.com

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words ?believe?, ?may?, ?plan?, ?will?, ?estimate?, ?continue?, ?anticipate?, ?intend?, ?expect? and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDIOME PHARMA CORP
12/08 CARDIOME PHARMA : Announces Commercial Launch of Xydalba(TM) (dalbavancin) in th..
11/29 CARDIOME PHARMA : Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
11/07 CARDIOME PHARMA : Reports Third Quarter 2016 Financial Results
11/01 CARDIOME PHARMA : to Reschedule Release of Third Quarter 2016 Financial Results
10/28 CARDIOME PHARMA : to Hold Third Quarter 2016 Financial Results Conference Call o..
10/14 CARDIOME PHARMA : Announces Initiation of Commercial Operations in Canada, Eh
08/16 CARDIOME PHARMA : Announces Recent Insider Purchases
08/09 CARDIOME PHARMA : Announces XYDALBA(TM) Single Dose Infusion Approval by Europea..
08/09 CARDIOME PHARMA : Reports Second Quarter 2016 Financial Results
08/08 CARDIOME PHARMA : Announces the Addition of Two Key Members to its Management Te..
More news
Sector news : Biopharmaceuticals
02:05pDJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
More sector news : Biopharmaceuticals
News from SeekingAlpha
11/09 Cardiome Pharma's (CRME) CEO Dr. Bill Hunter on Q3 2016 Results - Earnings Ca..
11/07 Cardiome Pharma beats by $0.01, misses on revenue
11/06 Notable earnings before Monday?s open
08/10 Cardiome Pharma's (CRME) CEO Bill Hunter on Q2 2016 Results - Earnings Call T..
08/10 Single-dose regimen for Cardiome's Xydalba OK'd in Europe
Advertisement
Financials ( CAD)
Sales 2016 32,5 M
EBIT 2016 -19,3 M
Net income 2016 -24,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 3,71x
Capi. / Sales 2017 2,95x
Capitalization 121 M
More Financials
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,3  CAD
Spread / Average Target 198%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Jennifer Archibald Chief Financial Officer
Harold H. Shlevin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP-64.02%91
BIOGEN INC-6.87%62 997
CSL LIMITED-8.47%32 515
ALEXION PHARMACEUTICAL..-33.95%28 255
BIOMARIN PHARMACEUTICA..-20.28%14 363
GRIFOLS SA-21.37%11 420
More Results